Pharmaceutical StrategyNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Shutters Internal UnitSalvado•Jun 5, 2026
Pharma StrategyNovo Nordisk's 24.9% Rally Validates AI Licensing Over Internal Cell TherapySalvado•May 31, 2026
Corporate StrategyNovo Nordisk Closes Internal Cell Therapy Unit, Licenses Program to AI-Native Cellular IntelligenceSalvado•May 21, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingSalvado•May 18, 2026
